I'm fine to answer in French.
Dr. Nickerson talked about the DNDi model in place at the international level. Under the model, partnerships with pharmaceutical companies like Sanofi have been established to carry out projects together.
The key to DNDi's success is that it's a virtual pharmaceutical company. That means it can leverage the expertise of scientists and people from all over the world. The initiative was the result of a six-way partnership, including the Malaysian and Indian governments, as well as other organizations. It's really a wonderful model, and it shows that, when all of these stakeholders come together, it's possible to create something at a much lower cost.
To answer your second question, I would say that it does exist elsewhere. For example, there is pricing competition. We come up with prices and people apply to get them. That's another way of going about it. Of course, it always takes money to do this kind of thing, so how does that money become available?
From a government standpoint, it's important to weigh the advantages against the drug costs. In Canada, a large chunk of the health care budget goes to medications. If we paid less for medications, we could do more in other health care areas. At the end of the day, it's about cost versus benefit.
What I've observed over the years is that investing in other models benefits the population because people gain access to drugs. Canada would also benefit. We have an excellent health care system, one that provides people with better support than is available in other parts of the world where people don't have that safety net. If we pay less for drugs in Canada, that would leave more money for other things, and that investment could be used to fund this other model, which also has the potential for a global impact.
Jason, would you like to add?